An open-label, pilot study to evaluate the benefits of using lyophilized human milk-derived nutritional product (NeoLact 70 – 1.55 g) as an immune-nutritional supplement in premature infants discharged from NICU

Gowtham R, Anisha Afza, Shankar Shankar, Lingaraju Subbanna
{"title":"An open-label, pilot study to evaluate the benefits of using lyophilized human milk-derived nutritional product (NeoLact 70 – 1.55 g) as an immune-nutritional supplement in premature infants discharged from NICU","authors":"Gowtham R, Anisha Afza, Shankar Shankar, Lingaraju Subbanna","doi":"10.32677/ijch.v8i12.3213","DOIUrl":null,"url":null,"abstract":"Background: Premature and low birth weight (LBW) infants are at increased risk of having inadequate growth in post-discharge periods. In this study, lyophilized human milk was used as an immune-nutrition supplement along with breastfeeding for a period of 1 month in preterm infants discharged from neonatal intensive care unit (NICU). Objectives: Primary objective was to assess the percentage change in serum immunoglobulins for the duration of supplementation, and secondary objectives were to correlate changes in immunoglobulins to number of episodes of infections including respiratory infections and diarrhea, requirement of antibiotics, weight gain, and episodes of feed intolerance during the study period. Methods: A total of 10 preterm and LBW infants were included in the study at the time of discharge from NICU after satisfying the inclusion and exclusion criteria. The serum immunoglobulins were estimated at baseline and at end of the study, other parameters such as episodes of infections, feed intolerance, and weight gain were recorded on the weekly follow-up visits. All the infants received supplementation with NeoLact 70 – 1.55 g on a TID frequency along with the regular breastfeeding for a period of 1-month post-discharge from NICU and were followed up on a weekly basis. Results: Ten infants completed the study, mean birth weight and gestational age were 1779.4±576 gm and 33.5±4.9 weeks, respectively. There was increase in immunoglobulins IgA, IgE, IgG, and IgM by 38.29%, 85.36%, 17.45%, and 48.25%, respectively, from baseline to end of study. None of the infants experienced feeding intolerance, diarrhea, abdominal distension, fever, respiratory infections, or rehospitalizations, none of the infants required antibiotics or probiotics during the study period. The average weight gain in the 1st, 2nd, 3rd, and 4th week of supplementation was 28.42 g/day, 31.57 g/day, 35.17 g/day, and 39.24 g/day, respectively, with a mean weight gain of 30.4 g/day achieved for the entire duration of the study. Conclusion: The immune-nutritional supplementation with lyophilized human milk (NeoLact 70 – 1.55 g) helps to ensure exclusive human milk diet post-discharge and reduce the risk of infections, diarrhea, and rehospitalization through the enhancement of immunoglobulins and ensuring optimal weight gain. However, these results should be confirmed through multicentric studies with larger sample size. Supplementation with NeoLact 70 – 1.55 g can clinically benefit premature and LBW infants post-discharge.","PeriodicalId":22476,"journal":{"name":"The Indian journal of child health","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Indian journal of child health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32677/ijch.v8i12.3213","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Premature and low birth weight (LBW) infants are at increased risk of having inadequate growth in post-discharge periods. In this study, lyophilized human milk was used as an immune-nutrition supplement along with breastfeeding for a period of 1 month in preterm infants discharged from neonatal intensive care unit (NICU). Objectives: Primary objective was to assess the percentage change in serum immunoglobulins for the duration of supplementation, and secondary objectives were to correlate changes in immunoglobulins to number of episodes of infections including respiratory infections and diarrhea, requirement of antibiotics, weight gain, and episodes of feed intolerance during the study period. Methods: A total of 10 preterm and LBW infants were included in the study at the time of discharge from NICU after satisfying the inclusion and exclusion criteria. The serum immunoglobulins were estimated at baseline and at end of the study, other parameters such as episodes of infections, feed intolerance, and weight gain were recorded on the weekly follow-up visits. All the infants received supplementation with NeoLact 70 – 1.55 g on a TID frequency along with the regular breastfeeding for a period of 1-month post-discharge from NICU and were followed up on a weekly basis. Results: Ten infants completed the study, mean birth weight and gestational age were 1779.4±576 gm and 33.5±4.9 weeks, respectively. There was increase in immunoglobulins IgA, IgE, IgG, and IgM by 38.29%, 85.36%, 17.45%, and 48.25%, respectively, from baseline to end of study. None of the infants experienced feeding intolerance, diarrhea, abdominal distension, fever, respiratory infections, or rehospitalizations, none of the infants required antibiotics or probiotics during the study period. The average weight gain in the 1st, 2nd, 3rd, and 4th week of supplementation was 28.42 g/day, 31.57 g/day, 35.17 g/day, and 39.24 g/day, respectively, with a mean weight gain of 30.4 g/day achieved for the entire duration of the study. Conclusion: The immune-nutritional supplementation with lyophilized human milk (NeoLact 70 – 1.55 g) helps to ensure exclusive human milk diet post-discharge and reduce the risk of infections, diarrhea, and rehospitalization through the enhancement of immunoglobulins and ensuring optimal weight gain. However, these results should be confirmed through multicentric studies with larger sample size. Supplementation with NeoLact 70 – 1.55 g can clinically benefit premature and LBW infants post-discharge.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一项开放标签的试点研究,旨在评估使用冻干人乳衍生营养品(NeoLact 70 - 1.55 g)作为新生儿重症监护病房出院早产儿免疫营养补充剂的益处
背景:早产和低出生体重(LBW)婴儿在出院后生长不良的风险增加。在这项研究中,冻干人乳作为免疫营养补充剂与母乳喂养一起用于从新生儿重症监护病房(NICU)出院的早产儿,为期1个月。目的:主要目的是评估补充期间血清免疫球蛋白的百分比变化,次要目的是将免疫球蛋白的变化与研究期间感染发作次数(包括呼吸道感染和腹泻)、抗生素需求、体重增加和饲料不耐受发作联系起来。方法:选取10例符合纳入和排除标准的早产儿和低体重儿在新生儿重症监护病房出院时纳入研究。在基线和研究结束时评估血清免疫球蛋白,在每周随访中记录其他参数,如感染发作、饲料不耐受和体重增加。所有婴儿在新生儿重症监护室出院后1个月的时间内,以TID频率补充NeoLact 70 - 1.55 g,并定期母乳喂养,每周随访一次。结果:10例婴儿完成研究,平均出生体重为1779.4±576 gm,平均胎龄为33.5±4.9周。免疫球蛋白IgA、IgE、IgG和IgM较研究结束时分别升高38.29%、85.36%、17.45%和48.25%。在研究期间,没有婴儿出现喂养不耐受、腹泻、腹胀、发烧、呼吸道感染或再次住院,没有婴儿需要抗生素或益生菌。在第1周、第2周、第3周和第4周,平均体重增加分别为28.42 g/天、31.57 g/天、35.17 g/天和39.24 g/天,在整个研究期间平均体重增加30.4 g/天。结论:补充冻干人乳(NeoLact 70 - 1.55 g)免疫营养有助于保证出院后的纯母乳饮食,通过增强免疫球蛋白,降低感染、腹泻和再住院的风险,并确保最佳增重。然而,这些结果需要通过更大样本量的多中心研究来证实。新生儿出院后补充NeoLact 70 - 1.55 g对早产儿和低体重婴儿有临床益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Clinical and etiopathological profile of pancytopenia in children (1-18 years): A study from tertiary care center of Bundelkhand region, central India Urinary tract infection in pediatric patients – Recent updates Pediatric autism spectrum disorder: Role of yoga prana vidya system as complementary medicine in accelerating patient progress An observational study to evaluate weight gain of exclusively breastfed infants who feed only while sleeping Fibular hemimelia in a neonate
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1